What are the predictors of malignancy in inflammatory bowel disease?
Turkish Journal of Medical Sciences · 15.08.2025 · 55 (4) · 846-854
DOI: 10.55730/1300-0144.6036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Turkish Journal of Medical Sciences, online erschienen am 15.08.2025. Verfasst von Zülal Istemihan und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterohepatology, Department of Internal Medicine, İstanbul Faculty of Medicine, İstanbul University, İstanbul, Turkiye. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Neoplasms. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/aimː This study aims to investigate the prevalence of malignancy in patients with inflammatory bowel disease (IBD) followed up in a tertiary reference center. Materials and methodsː IBD patients with at least 6 months of follow-up from the gastroenterology clinic between 2000 and 2022 wereevaluated retrospectively in a tertiary center. Patient information was obtained from the patient registration system. Resultsː There were 697 patients in the study, 320 (45.9%) of these were female. The mean age of the patients at IBD diagnosis was 33.4± 13.1 years. The mean follow-up time was 93.1 ± 64.8 (median 84, IQR (25–75) (36–144)) months. IBD types were as; 315 (45.2%) hadulcerative colitis, and 382 (54.8%) had Crohn’s disease. Before the diagnosis of IBD, 10 patients (1.4%) had a history of malignancy. Theprevalence of malignancy after the diagnosis of IBD was 13 (1.9%). There was a relationship between malignancy and older age, higherBMI, and female sex in survival analysis (p < 0.05). There was no correlation with disease type and malignancy (p = 0.820). When thepatients who developed malignancy in IBD were compared in terms of the immunomodulators and biological agents used by the patients who did not develop malignancy, there was no statistical difference between the two groups (p > 0.05). Conclusionː Older age, higher BMI, and female sex were found to be at risk for the development of malignancy in IBD, although norelationship was found with the use of immunomodulators, biological agents, or disease type.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterohepatology, Department of Internal Medicine, İstanbul Faculty of Medicine, İstanbul University, İstanbul, Turkiye.
- Department of Internal Medicine, İstanbul Faculty of Medicine, İstanbul University, İstanbul, Turkiye.
- Department of Pathology, İstanbul Faculty of Medicine, İstanbul University, İstanbul, Turkiye.
ORCID-Profile: Zülal Istemihan, Bilger Çavuş, Ali Emre Bardak, Ayşe Merve Kirkoğlu, Cansu Kiziltaş, Rüveyda Silay, İbrahim Volkan Şenkal, Ziya Imanov, Kenan Nuriyev, Aynure Rüstemzade, Sezen Genç, Mine Güllüoğlu, Aslı Çifcibaşi Örmeci, Kadir Demir, Fatih Beşişik, Sabahattin Kaymakoğlu, Filiz Akyüz
Zitieren
APA
Istemihan, Z., Çavuş, B., Bardak, A. E., Kirkoğlu, A. M., Kiziltaş, C., Silay, R., Şenkal, İ. V., Imanov, Z., Nuriyev, K., Rüstemzade, A., Genç, S., Güllüoğlu, M., Çifcibaşi Örmeci, A., Demir, K., Beşişik, F., Kaymakoğlu, S., & Akyüz, F. (2025). What are the predictors of malignancy in inflammatory bowel disease?. Turkish Journal of Medical Sciences, 55(4), 846-854. https://doi.org/10.55730/1300-0144.6036
Vancouver
Istemihan Z, Çavuş B, Bardak AE, Kirkoğlu AM, Kiziltaş C, Silay R, et al. What are the predictors of malignancy in inflammatory bowel disease?. Turkish Journal of Medical Sciences. 2025;55(4):846-854. doi:10.55730/1300-0144.6036
BibTeX
@article{Istemihan2025,
author = {Istemihan, Zülal and Çavuş, Bilger and Bardak, Ali Emre and Kirkoğlu, Ayşe Merve and Kiziltaş, Cansu and Silay, Rüveyda and Şenkal, İbrahim Volkan and Imanov, Ziya and Nuriyev, Kenan and Rüstemzade, Aynure and Genç, Sezen and Güllüoğlu, Mine and Çifcibaşi Örmeci, Aslı and Demir, Kadir and Beşişik, Fatih and Kaymakoğlu, Sabahattin and Akyüz, Filiz},
title = {What are the predictors of malignancy in inflammatory bowel disease?},
journal = {Turkish Journal of Medical Sciences},
year = {2025},
volume = {55},
number = {4},
pages = {846--854},
doi = {10.55730/1300-0144.6036}
}
EUVIMED